“We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share.”,” Mizuho’s analyst wrote.
Separately, Zacks Investment Research upgraded shares of Xeris Pharmaceuticals from a hold rating to a buy rating and set a $20.00 price target on the stock in a report on Wednesday, October 17th. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average target price of $23.60.
XERS stock opened at $20.62 on Tuesday. Xeris Pharmaceuticals has a 52-week low of $15.75 and a 52-week high of $27.98. The company has a quick ratio of 16.55, a current ratio of 16.55 and a debt-to-equity ratio of 0.33.
Xeris Pharmaceuticals (NASDAQ:XERS) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.07. The firm had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.30 million. As a group, analysts expect that Xeris Pharmaceuticals will post -7.3 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in shares of Xeris Pharmaceuticals during the second quarter valued at approximately $214,000. Bank of New York Mellon Corp purchased a new position in Xeris Pharmaceuticals during the third quarter valued at approximately $262,000. BlackRock Inc. purchased a new position in Xeris Pharmaceuticals during the second quarter valued at approximately $475,000. Dean Capital Investments Management LLC purchased a new position in Xeris Pharmaceuticals during the second quarter valued at approximately $563,000. Finally, Millennium Management LLC purchased a new position in Xeris Pharmaceuticals during the second quarter valued at approximately $1,898,000. Institutional investors and hedge funds own 50.49% of the company’s stock.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.